Parexel International (ma) Corporation
Location
Massachusetts
Founded
1983-02-28
Website
Risk Signals
451 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Parexel International (ma) Corporation
Live alerts from global media, monitored by Business Radar
2022-07-14 (bizcommunity.com)
UFS acquires clinical research company
The University of the Free State (UFS) has concluded a deal with Parexel International to acquire 100% shares in the latter's locally-based clinical research business, Farmovs-Parexel...
Read more
2021-03-08 (businesswire.com)
Alation Launches New Company Initiatives to Further Support Women in Data and Technology
Alation Inc., the leader in enterprise data intelligence solutions, today announced new company initiatives to further support women in data and techn
Read more
2016-09-26 (businesswire.com)
PAREXEL Announces Execution of Definitive Agreement to Acquire ExecuPharm
PAREXEL today announced that the Company entered into a definitive agreement to acquire ExecuPharm, Inc.
Read more
2016-01-19 (businesswire.com)
PAREXEL Announces Execution of Definitive Agreement to Acquire Health Advances
PAREXEL today announced that the Company has entered into a definitive agreement to acquire all outstanding equity securities of Health Advances, an i
Read more
2014-06-30 (outsourcing-pharma.com)
Pfizer offers update on risk-sharing deals with Icon, Parexel
Three years after Pfizer began strategic partnerships with CROs Icon and Parexel, and the companies are still ironing out differences and tweaking their relationships, Mark Sanders, senior director of global sourcing, told attendees at DIA’s annual conference.
Read more
2010-09-21 (outsourcing-pharma.com)
GSK selects Parexel and PPD as strategic CROs
Parexel and PPD forge new strategic links with GSK as UK firm becomes latest Big Pharma to refocus CRO relationships.
Read more
2010-09-20 (outsourcing-pharma.com)
GSK selects Parexel and PPD as strategic CROs
Parexel and PPD forge new strategic links with GSK as UK firm becomes latest Big Pharma to refocus CRO relationships.
Read more
(pe-insights.com)
Private equity majors circle $9bn-valued Parexel as Pamplona Capital mulls exit options | Private Equity Insights
Contract research firm Parexel is said to garner takeover interest from Private equity giant EQT and a consortium of three other buyout majors.
Read more
(biospace.com)
Clinical Trials Market Size to Increase USD 153.59 Billion by 2033
According to Nova One Advisor, the global clinical trials market size was estimated at USD 81.90 billion in 2023 and it is projected to increase USD 153.59 billion by 2033 with a CAGR of 6.49% from 2024 to 2033.
Read more